OrganoTherapeutics Joins Michael J. Fox Foundation’s LRRK2 Therapeutics Exchange
OrganoTherapeutics has joined a new collaborative effort spearheaded by the Michael J. Fox Foundation for Parkinson’s Research: the LRRK2 Investigative Therapeutics Exchange - LITE.
This program brings together a group of partners—including biotech innovators, academic researchers, and drug developers—with one mission: to accelerate therapeutic progress for LRRK2-associated Parkinson’s disease through open collaboration and shared resources.
Why LRRK2?
Mutations in the LRRK2 gene are among the most common genetic causes of Parkinson’s disease, making it a critical target for disease-modifying treatments. The Exchange aims to support this mission by:
Sharing proprietary and non-proprietary data across partners
Making tools and models more accessible for testing LRRK2-targeting therapies
Enabling faster, more reproducible evaluation of candidate compounds
Our Role in the Exchange
At OrganoTherapeutics, we’re contributing our physiologically relevant midbrain organoid models, which are suited for studying Parkinson’s pathology in a human-like context. Our organoids help researchers:
Investigate LRRK2-driven cellular mechanisms
Validate drug candidates in reproducible in vitro systems
Reduce the gap between basic discovery and clinical translation
A Shared Vision
We’re honored to collaborate with the Michael J. Fox Foundation and fellow Exchange partners who share our commitment to bring more reliable models, better data, and smarter therapies to the forefront of Parkinson’s disease research.
To learn more about the program, visit the Michael J. Fox Foundation’s announcement.